Non-alcoholic Fatty Liver Disease

• EMA approval · 2026-04-09
  EMA Authorised: Kayshild (semaglutide) — Novo Nordisk A/S

  EU medicines regulator authorised Kayshild (semaglutide) by Novo Nordisk A/S for non-alcoholic fatty liver disease and liver cirrhosis, with…

• EMA approval · 2025-11-10
  EMA Authorised: Rezdiffra (resmetirom) — Madrigal Pharmaceuticals EU Limited

  EMA authorised Rezdiffra (resmetirom) for non-alcoholic fatty liver disease and cirrhosis of the liver, granted with conditional approval.

• EMA approval · 2025-06-20
  First treatment against liver scarring caused by a type of ‘fatty liver disease’

  EMA approved the first treatment for liver scarring caused by a fatty liver disease. The drug is indicated for adults with moderate to advan…